Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 3/20 | 0.40 |
| ▸ | RXRB | P28702 | 3/20 | 0.40 |
| ▸ | RXRG | P48443 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17072154 | 0.85 | RXRA (0.37) | TACR1GPR35ALDH1A1LMNARXRA | |
| SCHEMBL23636332 | 0.83 | TP53 (0.48) | CES2MAPTALDH1A1LMNA | |
| SCHEMBL2497436 | 0.81 | EPHX2 (0.44) | CES2ALDH1A1LMNA | |
| SCHEMBL16776735 | 0.81 | RXRB (0.38) | RXRARXRBRXRG | |
| SCHEMBL15397669 | 0.77 | TACR1 (0.59) | TACR1CES2MAPTP2RX1RXRA | |
| SCHEMBL15720332 | 0.75 | HTT (0.35) | TACR1MAPTALDH1A1RXRARXRB | |
| SCHEMBL17221855 | 0.75 | TDP1 (0.34) | ALDH1A1 | |
| SCHEMBL1972926 | 0.74 | TACR1 (0.43) | TACR1CES2MAPTP2RX1ALDH1A1 | |
| SCHEMBL15913794 | 0.73 | AR (0.43) | MAPTGPR35P2RX1 | |
| SCHEMBL22527596 | 0.73 | NOTUM (0.36) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | TACR1 13/4885CES2 3529/4885MAPT 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.